Recent News

• 07.24.2026 - Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
• 07.15.2026 - Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
• 07.14.2026 - Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
• 06.25.2026 - Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
• 06.17.2026 - Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
• 06.09.2026 - Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
• 05.27.2026 - Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
• 05.20.2026 - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
• 05.11.2026 - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
• 05.06.2026 - Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

Recent Filings

• 07.02.2026 - 8-K Current report
• 07.02.2026 - 8-K Current report
• 07.02.2026 - EX-99.1 EX-99.1
• 06.26.2026 - 8-K Current report
• 05.20.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors